Enterprise Value
-4.143M
Cash
65.92M
Avg Qtr Burn
-8.11M
Short % of Float
1.81%
Insider Ownership
5.56%
Institutional Own.
13.18%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rilvegostomig (PD-1/TIGIT) Details Non-small cell lung carcinoma, Cancer, Hepatobiliary cancer | Phase 3 Data readout | |
COM701 + Opdivo (nivolumab) +/- BMS-986207 Details Ovarian cancer, Cancer, Endometrial cancer | Phase 1/2 Update | |
COM701 + Opdivo (nivolumab) Details Solid tumor/s, Cancer, Metastatic breast cancer | Phase 1b Update | |
COM902 (TIGIT) Details Cancer, Advanced malignancies | Phase 1 Data readout | |
COM701+COM902 +Pembrolizumab Details Cancer, Platinum-resistant ovarian cancer | Phase 1 Data readout | |
COM701+COM902 +Pembrolizumab Details Cancer, Colorectal cancer | Phase 1 Data readout | |
COM701 (PVRIG) Details Ovarian cancer, Colorectal cancer , Non-small cell lung carcinoma, Breast cancer, Endometrial cancer, Cancer | Failed Discontinued |